We observed significant hypermethylation in 4 of the 10 target genes (MAN1A1, EPB41, HSD17B13, and MYOM2) in primary prostate cancer patient tumors (n = 503) compared to normal prostatic samples (n = 50) (p ≤ 0.05) (Figure 7A). The gene discussed is HSD17B13; the disease is prostate carcinoma.